Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...
Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...
Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...
US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...
Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ETCompany ParticipantsBreno Toledo Pires de Oliveira - Chief ...
The Healthy @Reader's Digest on MSN8h
28 Heart Health Secrets Cardiologists Want You to KnowTime is a scarce resource at the doctor’s office, with the average visit lasting nearly 19 minutes, according to 2023 research published in Journal of the American Medical Association Health Forum.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study.
Pancheros Mexican Grill in Cedar Falls is partnering with the University of Northern Iowa by selling 3,000 $2 burritos for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback